Grufity logoGrufity logo

BMY

79.92USD-0.78(-0.97%)Market Closed

Bristol-Myers Squibb Co

Market Summary

USD79.92-0.78Market Closed
-0.97%

BMY Alerts

BMY Stock Price

RSI Chart

Valuation

Market Cap

163.4B

Price/Earnings

24.47

Price/Sales

3.5

Price/Cashflow

11.82

MarketCap/EBT

21.18

Price/Sales

Profitability

EBT Margin

16.50%

Return on Equity

20.44%

Return on Assets

6.8%

Fundamentals

Revenue

Revenue (TTM)

46.7B

Revenue Y/Y

-3.49%

Revenue Q/Q

-5.63%

Earnings

Earnings (TTM)

6.7B

Earnings Y/Y

3.88%

Earnings Q/Q

13.02%

Price Action

52 Week Range

54.4281.44
(Low)(High)

Last 7 days

1.1%

Last 30 days

1.5%

Last 90 days

17.1%

Trailing 12 Months

45%

Financial Health

Current Ratio

1.42

Debt/Equity

1.19

Debt/Cashflow

0.36

Investor Care

Dividend Yield

2.81%

Dividend/Share (TTM)

2.16

Buy Backs (1Y)

4.21%

Diluted EPS (TTM)

3.07

Peers (Alternatives to Bristol-Myers Squibb)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
459.8B
96.0B
3.36% 10.92%
24
4.79
5.02% 7.14%
342.0B
29.2B
3.40% 51.66%
60.08
11.76
5.34% 1.02%
266.2B
99.7B
5.27% -0.30%
9.08
2.63
43.92% 53.21%
255.3B
57.2B
9.81% 53.57%
15.4
4.47
35.88% 197.59%
163.4B
46.7B
1.45% 45.00%
24.47
3.5
2.79% 223.53%
MID-CAP
5.5B
4.4B
-19.18% -13.13%
-46.93
1.26
1.80% 57.67%
SMALL-CAP
1.9B
628.4M
6.56% -55.63%
-4.08
3.1
64.35% -18.14%
1.9B
659.0M
4.71% 18.39%
32.36
2.95
16.78% -53.92%
1.5B
-
9.73% -64.43%
-0.54
1.95
-4.11% -144.36%
1.2B
112.7M
-1.62% -29.86%
-10.75
7.76
-54.94% 40.20%
1.1B
3.1M
14.43% -23.02%
-3.57
108.75
-77.09% -12.24%
1.0B
23.5M
5.01% 25.95%
-12.31
166.87
243.57% -1.04%
945.9M
373.2M
1.00% -20.26%
4.56
2.34
-0.39% -38.45%
283.2M
49.7M
-17.14% -53.07%
-8.71
5.67
28.95% 32.80%
68.8M
2.6B
-43.99% -88.43%
-0.03
0.02
-13.88% -4855.92%

Financials for Bristol-Myers Squibb

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue-0.9%46,73847,14446,96046,38545,468
  S&GA Expenses1.8%7,9027,7607,8557,6908,057
  R&D Expenses-8.0%9,60610,43911,38911,35412,497
Earnings Before Taxes0.7%7,7127,6607,2558,098-4,211.00
Net Income0.9%6,6776,6176,2516,994-5,405.00
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets-2.2%98,196100,357103,034109,314110,893
  Current Assets-11.2%26,79630,18630,12133,26231,443
    Cash Equivalents-26.0%7,95710,75012,36913,97913,540
  Inventory-3.2%2,0742,1422,1042,0952,163
  Net PPE1.1%6,0355,9706,0476,0495,868
  Goodwill3.3%21,11220,44620,50020,50220,519
Liabilities-3.3%65,46267,69671,38973,30873,609
  Current Liabilities-9.5%18,93020,91522,82121,86821,460
.    Short Term Borrowings-57.0%2,1324,9537,5224,948-
  Long Term Debt-6.9%38,86941,75344,74744,369-
    LT Debt, Current-59.0%1,9034,6467,2974,764-
    LT Debt, Non Current-0.4%36,96637,10737,45039,60539,677
Shareholder's Equity0.2%32,67132,60031,58035,94637,213
  Retained Earnings1.9%24,67524,21723,94823,82022,625
  Additional Paid-In Capital1.3%44,95644,37543,75644,36144,292
Shares Outstanding-0.4%2,1262,1352,1292,220-
Minority Interest3.3%6361656071
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations-10.3%13,81715,39616,19516,20715,820
  Share Based Compensation-5.4%471498539583621
Cashflow From Investing-143.7%-1,874.00-769.00-300.00-538.00-12,751.00
Cashflow From Financing-18.5%-17,683.00-14,920.00-14,582.00-16,224.00-8,774.00
  Dividend Payments1.4%4,5884,5244,4734,3964,318
  Buy Backs2.1%8,4528,2769,5126,2875,001

Risks

What is the probability of a big loss on BMY?

48.1%


Probability that Bristol-Myers Squibb stock will be more than 20% underwater in next one year

1.9%


Probability that Bristol-Myers Squibb stock will be more than 30% underwater in next one year.

0%


Probability that Bristol-Myers Squibb stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does BMY drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Bristol-Myers Squibb was unfortunately bought at previous high price.

Returns

Cumulative Returns on BMY

12.6%


10-Year Cumulative Returns

5.0%


7-Year Cumulative Returns

8.5%


5-Year Cumulative Returns

13.5%


3-Year Cumulative Returns

What are the long-term rolling returns for BMY?

FIve years rolling returns for Bristol-Myers Squibb.

Which funds bought or sold BMY recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-23
Eagle Bay Advisors LLC
REDUCED
-4.59
-79,383
591,000
0.36%
2022-11-23
Toroso Investments, LLC
ADDED
16.53
316,000
4,491,000
0.19%
2022-11-23
Invst, LLC
REDUCED
-3.37
-40,000
304,000
0.05%
2022-11-22
Coombe, Bender & Co LLC
REDUCED
-0.24
-170,000
1,983,000
1.76%
2022-11-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
NEW
-
41,320,000
41,320,000
0.48%
2022-11-22
B. Riley Wealth Advisors, Inc.
ADDED
67.83
5,030,000
14,184,000
0.43%
2022-11-22
CVA Family Office, LLC
REDUCED
-8.19
-61,000
336,000
0.09%
2022-11-22
Gibson Wealth Advisors LLC
UNCHANGED
-
-4,000
55,000
0.06%
2022-11-22
CONTINENTAL INVESTORS SERVICES, INC.
NEW
-
483,000
483,000
0.02%
2022-11-22
SMITH CHAS P & ASSOCIATES PA CPAS
ADDED
74.93
235,000
617,000
0.05%

1–10 of 46

Latest Funds Activity

Are funds buying BMY calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own BMY

Bristol-Myers Squibb News

TheStreet

Breaking Bank.7 hours ago

BMY Fair Value

Recent SEC filings of Bristol-Myers Squibb

View All Filings
Date Filed Form Type Document
Nov 14, 2022
4
Insider Trading
Nov 09, 2022
4
Insider Trading
Oct 26, 2022
10-Q
Quarterly Report
Oct 26, 2022
8-K
Current Report
Oct 04, 2022
4
Insider Trading
Oct 04, 2022
4
Insider Trading
Oct 04, 2022
4
Insider Trading
Oct 04, 2022
4
Insider Trading
Oct 04, 2022
4
Insider Trading
Oct 04, 2022
4
Insider Trading

Latest Insider Trading transactions for BMY

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-11-09
Powell Ann
SOLD
-1,307,310
80.45
-16,250
EVP, Chief Human Resources
2022-11-07
VESSEY RUPERT
ACQUIRED
3,067,530
58.3136
52,604
EVP, Research & Early Dev.
2022-11-07
VESSEY RUPERT
SOLD
-3,621,380
78.88
-45,910
EVP, Research & Early Dev.
2022-09-20
Caforio Giovanni
SOLD
-1,742,750
69.71
-25,000
Board Chair and CEO
2022-09-15
Caforio Giovanni
SOLD
-3,592,000
71.84
-50,000
Board Chair and CEO
2022-09-14
Powell Ann
SOLD
-1,768,750
70.75
-25,000
EVP, Chief Human Resources
2022-09-13
Elkins David V
SOLD
-9,551,170
71.3034
-133,951
EVP, Chief Financial Officer
2022-09-13
Elkins David V
ACQUIRED
5,977,700
48.49
123,277
EVP, Chief Financial Officer
2022-07-01
Hirawat Samit
SOLD (Taxes)
-367,756
76.84
-4,786
EVP,Chief Med.Offr.,Drug Dev.
2022-07-01
Weese Michelle
SOLD (Taxes)
-52,404.9
76.84
-682
EVP, Corporate Affairs

1–10 of 50

Giovanni Caforio
32200
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

BMY Income Statement

2022-09-30
CONSOLIDATED STATEMENTS OF EARNINGS - USD ($)
$ in Millions
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Total Revenues$ 11,218$ 11,624$ 34,753$ 34,400
Cost of products sold[1]2,3532,2917,5447,584
Marketing, selling and administrative1,9301,7885,5485,336
Research and development2,4182,9806,9997,677
Acquired IPRD302717631,070
Amortization of acquired intangible assets2,4182,5467,2527,606
Other (income)/expense, net(140)(409)793(1,113)
Total Expenses9,0099,46728,89928,160
Earnings Before Income Taxes2,2092,1575,8546,240
Provision for Income Taxes6016051,5341,598
Net Earnings1,6081,5524,3204,642
Noncontrolling Interest261520
Net Earnings Attributable to BMS$ 1,606$ 1,546$ 4,305$ 4,622
Earnings per common share attributable to BMS, basic (in usd per share)$ 0.75$ 0.70$ 2.01$ 2.08
Earnings per common share attributable to BMS, diluted (in usd per share)$ 0.75$ 0.69$ 2.00$ 2.05
Net product sales    
Total Revenues$ 10,813$ 11,243$ 33,606$ 33,446
Alliance and other revenues    
Total Revenues$ 405$ 381$ 1,147$ 954
[1]Excludes amortization of acquired intangible assets

BMY Balance Sheet

2022-09-30
CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Current Assets:  
Cash and cash equivalents$ 7,734$ 13,979
Marketable debt securities1,2932,987
Receivables9,6139,369
Inventories2,0742,095
Other current assets6,0824,832
Total Current Assets26,79633,262
Property, plant and equipment6,0356,049
Goodwill21,11220,502
Other intangible assets38,17942,527
Deferred income taxes1,3291,439
Other non-current assets4,7455,535
Total Assets98,196109,314
Current Liabilities:  
Short-term debt obligations2,1324,948
Accounts payable2,5952,949
Other current liabilities14,20313,971
Total Current Liabilities18,93021,868
Deferred income taxes2,8814,501
Long-term debt36,96639,605
Other non-current liabilities6,6857,334
Total Liabilities65,46273,308
Commitments and contingencies
Bristol-Myers Squibb Company Shareholders’ Equity:  
Preferred stock00
Common stock292292
Capital in excess of par value of stock44,95644,361
Accumulated other comprehensive loss(841)(1,268)
Retained earnings24,67523,820
Less cost of treasury stock(36,411)(31,259)
Total Bristol-Myers Squibb Company Shareholders’ Equity32,67135,946
Noncontrolling interest6360
Total Equity32,73436,006
Total Liabilities and Equity$ 98,196$ 109,314